Health Opportunities and Promoters of Equitable Screening for Lung Cancer (HOPES)

March 14, 2024 updated by: Efren J. Flores, M.D., Massachusetts General Hospital

Health Opportunities and Promoters of Equitable Screening for Lung Cancer (HOPES for Lung Cancer)

The goal of this clinical trial is to promote lung cancer screening (LCS) uptake among Hispanic current and former smokers. The main questions it aims to answer are:

  • What barriers do current and former Hispanic smokers face in the identification and documentation of their smoking status?
  • How can digital delivery of an educational video promote LCS uptake among current and former Hispanic smokers?

Participants will receive an educational video about lung cancer screening and complete brief, self-reported surveys afterwards.

Study Overview

Status

Active, not recruiting

Detailed Description

Lung cancer remains the leading cause of cancer-specific mortality in the US, and Hispanics experience worse lung cancer outcomes and die at higher rates due to advanced stage at presentation. Lung cancer screening (LCS) can save many lives through early lung cancer detection among Hispanic current and former smokers.

Still, without increasing efforts to improve smoking status disclosure and documentation and tailored interventions to promote LCS uptake among Hispanic current and former smokers, this underserved population will continue to demonstrate disparities in lung cancer survival. Based on prior research experience, Dr. Flores has adapted the NIMHD research framework by incorporating elements from Ford's evidence-based theoretical model to guide the following proposed study aims:

1) To elucidate barriers and facilitators to consistent identification and documentation of smoking status to promote LCS uptake among Hispanic current and former smokers; 2) To assess feasibility, acceptability, and reach of the digital delivery of an educational video to promote LCS uptake among Hispanic current and former smokers; 3) To explore the effect of the digital delivery of the educational video to increase interest, intent, and scheduling of LCS uptake among Hispanic current and former smokers.

Impact: The successful completion of this research will serve as a foundation for developing novel interventions to overcome disparities and advance equity in lung cancer outcomes among Hispanics and other vulnerable populations.

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Investigators chose to restrict eligibility to adults aged 50-80 with no personal history of lung cancer to meet the United States Preventive Services Task Force Guidelines for lung cancer screening. As the primary aim of this study is to address the disparities in lung cancer screening rates and outcomes for Hispanic individuals, only Hispanic-identifying patients will be eligible for participation. Further grants stemming from this project will include community-based outreach efforts to extend the testing and dissemination of this intervention to other underrepresented groups.

Description

Inclusion Criteria:

  • Must be 50-80 years old
  • Are a current or former smoker (quit within 15 years, or a cumulative smoking status of > 20 pack-years)
  • Not currently enrolled in Lung Cancer Screening
  • Must speak English or Spanish

Exclusion Criteria:

  • Has a clinical cognitive inability to provide informed consent for participation in the study or complete a brief survey
  • Currently diagnosed with lung cancer
  • Currently enrolled in lung cancer screening
  • Have participated in the focus groups discussions from Aim 1

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Digital Outreach: Patient Gateway
Participants who list "Patient Gateway" as the preferred mode of contact in the electronic health record (EHR) system. Patient Gateway is an online patient portal that gives patients access to securely message their Mass General Brigham provider, request routine appointments, prescriptions and referral authorizations as well as view test results that were processed at a Mass General Brigham facility. Participants will receive the digital educational lung cancer screening video via their patient gateway account.
An educational video on lung cancer screening tailored to Hispanic current and former smokers.
Digital Outreach: Text
Participants who list "Text" as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video via a text message sent directly to their cell phone.
An educational video on lung cancer screening tailored to Hispanic current and former smokers.
Digital Outreach: Email
Participants who list "Email" as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video directly to the email they have listed.
An educational video on lung cancer screening tailored to Hispanic current and former smokers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant outreach (contact) of digital link
Time Frame: Year 3
Reach is defined as >20% of enrolled participants interacting with the digital delivery of the LCS educational video (i.e., partial or complete review of the LCS educational video).
Year 3

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant interaction with digital link
Time Frame: Year 3
Overall proportion of participants that click on the embedded link to the successfully digitally delivered LCS educational videos
Year 3
Participant attention of LCS video
Time Frame: Year 3
Duration of viewing the LCS video (i.e., partial or complete)
Year 3
Survey completion
Time Frame: Year 4
Overall proportion of survey completion by participants.
Year 4

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant baseline smoking status
Time Frame: Year 5
Identify salient participant characteristics obtained from the EHR (e.g., smoking status) among those that interacted with the digital delivery modality.
Year 5
Participant acceptability of intervention
Time Frame: Year 5
Investigate attributes of the intervention to guide future research and development to create such an intervention (for future trials)
Year 5

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Efren Flores, MD, Massachusetts General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 3, 2023

Primary Completion (Estimated)

January 31, 2028

Study Completion (Estimated)

January 31, 2028

Study Registration Dates

First Submitted

February 27, 2023

First Submitted That Met QC Criteria

March 22, 2023

First Posted (Actual)

March 27, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 14, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Clinical Trials on Educational Lung Cancer Screening (LCS) Video

3
Subscribe